Although the potential role of HER2 as a therapeutic target has been investigated in cancer patients, clinical studies of trastuzumab in combination with chemotherapy, and even the selection of HER2 protein overexpression for targeted therapy, have yielded disappointing results [5]. The gene discussed is ERBB2; the disease is cancer.